AP NEWS

CLASS ACTION UPDATE for MD and ABBV: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

August 29, 2018

NEW YORK, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.

MEDNAX, Inc. (NYSE: MD) Class Period: February 4, 2016 - July 27, 2017 Lead Plaintiff Deadline: September 10, 2018 Join the action: http://www.zlk.com/pslra-d/mednax-inc?wire=3

The lawsuit alleges: MEDNAX, Inc. made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (1) the Company’s business model was not sustainable; and (2) Mednax’s growth was in fact based upon suppressing physician compensation and enforcing non-compete agreements to deter physician defections.

On April 20, 2017, Mednax announced negative financial results for the first quarter of 2017. Then on July 28, 2017, during an earnings call, Mednax announced that the Company failed to complete any acquisitions of anesthesiologist practices during the second quarter and disclosed that any future acquisitions were unlikely. Following this news, shares of Mednax fell from a close of $56.49 on July 27, 2017, to a close of $47.73 per share the following day.

To learn more about the MD class action contact jlevi@levikorsinsky.com.

AbbVie Inc. (NYSE: ABBV) Class Period: May 30, 2018 Lead Plaintiff Deadline: September 24, 2018 Join the action: http://www.zlk.com/pslra-d/abbvie-inc?wire=3

The complaint alleges that AbbVie issued false and misleading statements, in both press releases and filings with the U.S. Securities and Exchange Commission, regarding the results of the Company’s $7.5 billion modified Dutch auction tender offer that expired on May 29, 2018 (the “Tender Offer”). Specifically, the complaint alleges that before the opening of trading on May 30, 2018, the Company announced that it expected to acquire 71.4 million of its shares tendered at or below $105 per share. As a result of this news, the price of AbbVie securities significantly increased. However, after the close of trading on May 30, 2018, the Company released materially different results for the Tender Offer due to certain omissions, announcing that the Company expected to acquire only those shares tendered at or below $103 per share. Upon this news, AbbVie shares fell from a close of $103.01 per share on May 30, 2018, to a close of $98.94 on May 31, 2018.

To learn more about the ABBV class action contact jlevi@levikorsinsky.com.

You have until the lead plaintiff deadlines to request the court appoint as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Levi & Korsinsky, LLPJoseph E. Levi, Esq.55 Broadway, 10th FloorNew York, NY 10006 jlevi@levikorsinsky.com Tel: (212) 363-7500Toll Free: (877) 363-5972Fax: (212) 363-7171www.zlk.com

AP RADIO
Update hourly